Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
IND filing for Phase 2 pediatric basket study on track for year-endGAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company ...
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment
Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.
Mena FN13d
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation For Descartes-08 For The Treatment Of Juvenile Dermatomyositis
has granted Rare Pediatric disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian's lead mRNA cell therapy candidate, is an autologous ...
Pharmabiz12d
US FDA grants rare paediatric disease designation to Cartesian Therapeutics’ Descartes-08 to treat juvenile dermatomyositis
US FDA grants rare paediatric disease designation to Cartesian Therapeutics’ Descartes-08 to treat juvenile dermatomyositis: Gaithersburg, Maryland Tuesday, September 10, 2024, ...
The Pharma Letter13d
FDA grants rare pediatric status for Cartesian’s Descartes-08
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease ...
Cartesian's Descartes-08 Granted Rare Pediatric Disease Designation By FDA To Treat JDM
Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, ...
Buy Rating for Cartesian Therapeutics Backed by FDA Designation and Promising Therapy Prospects
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the ...
Pharmaceutical Technology13d
Gefurulimab by Alexion Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.